1-(2-Sulfoxybenzol)-3,3-dimethyltriazen | 39201-85-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(2-Sulfoxybenzol)-3,3-dimethyltriazen
• 英文别名: Dimethylaminoazobenzolsulfonsaure；2-(dimethylaminodiazenyl)benzenesulfonic acid
• CAS: 39201-85-9
• 化学式: C₈H₁₁N₃O₃S
• 分子量: 229.26
• InChiKey: ZAPTZHDIVAYRQU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  90.7
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-氨基苯磺酸 在 二氧化氮 作用下， 反应 6.0h， 生成 1-(2-Sulfoxybenzol)-3,3-dimethyltriazen
  参考文献：
  名称：

  Abfallfreie Gas/Festkörper-Diazotierung mit Stickstoffdioxid und quantitative Triazensynthese ohne Flüssigphase

  摘要：

  Solid diazonium nitrates (2a-j) are quantitatively obtained by reaction of crystalline anilines (1a-j) with gaseous nitrogen dioxide. Solid diazonium salts react quantitatively with dimethylamine to give the triazenes (4a-j). Wastes that are typical for the previous syntheses of these compounds in solution are avoided. Atomic force microscopic (AFM) investigations indicate long-range molecular movements due to phase rebuilding. The features thus formed are related to the known crystal structures of the starting anilines. The diazotations run to completion, because, after accumulation of product molecules, phase transformation to give the product lattices leads to crystal disintegration and thus to formation of fresh surface over and over.

  DOI：

  10.1002/prac.19973390145

文献信息

• 3-ARYL PROPIOLONITRILE COMPOUNDS FOR THIOL LABELING
  申请人：UNIVERSITE DE STRASBOURG

  公开号：US20160145199A1

  公开（公告）日：2016-05-26

  The present invention relates to a process for labeling compounds comprising thiol moieties with 3-arylpropiolonitrile compounds, to 3-arylpropiolonitrile compounds substituted with tag moieties and to specific 3-arylpropiolonitrile linkers.

  本发明涉及一种将含硫醇基团的化合物用3-芳基丙炔腈化合物标记的方法，以及用标记基团取代的3-芳基丙炔腈化合物和特定的3-芳基丙炔腈连接剂。
• [EN] SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS<br/>[FR] HYDANTOÏNAMIDES SUBSTITUÉS UTILISÉS EN TANT QU'ANTAGONISTES D'ADAMTS7
  申请人：BAYER AG

  公开号：WO2021094436A1

  公开（公告）日：2021-05-20

  The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl or phenyl; R2 is hydrogen, cyano, halogen, alkylsulfonyl, alkyl, cycloalkyl or alkoxy; R3, R4, R5, R6, R7 and R8 are independently hydrogen, halogen, alkyl or alkoxy; most groups being optionally substituted; with the proviso that at least one of R2, R3, R4 is H; X1, X2, X3, X4, X5 and X6 are independently N or C; with the proviso that in each ring maximal one X is N.

  本申请涉及式(I)所示的取代脒酰胺作为ADAMTS7拮抗剂，涉及它们的制备过程，以及它们单独或组合用于治疗或预防疾病，特别是心血管疾病，包括动脉粥样硬化、冠心病(CAD)、外周血管病(PAD)、动脉闭塞性疾病或血管成形术后的再狭窄。R1是氢、烷基、环烷基、杂环烷基、杂芳基或苯基；R2是氢、氰基、卤素、烷基亚磺酰基、烷基、环烷基或烷氧基；R3、R4、R5、R6、R7和R8独立的是氢、卤素、烷基或烷氧基；大多数基团可被选择性地取代；条件是至少R2、R3、R4中的一个为H；X1、X2、X3、X4、X5和X6独立的是N或C；条件是每个环中最多只有一个X是N。
• [EN] SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS<br/>[FR] HYDANTOINAMIDES SUBSTITUÉS EN TANT QU'ANTAGONISTES D'ADAMTS7
  申请人：BAYER AG

  公开号：WO2021094434A1

  公开（公告）日：2021-05-20

  The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, 5- to 6-membered heteroaryl or phenyl; R2 is hydrogen or alkyl; A is 5-membered heteroaryl; Z is 6- to 10-membered aryl or 5- to 10-membered heteroaryl; all groups being optionally substituted.

  该申请涉及公式（I）的替代咪唑酰脲作为ADAMTS7拮抗剂，以及它们的制备方法，它们单独或与其他药物联合用于治疗或预防疾病，特别是心血管疾病，包括动脉粥样硬化、冠状动脉疾病（CAD）、外周血管疾病（PAD）、动脉闭塞病或血管成形术后再狭窄。R1为氢、烷基、环烷基、杂环烷基、5-至6-成员杂芳基或苯基；R2为氢或烷基；A为5-成员杂芳基；Z为6-至10-成员芳基或5-至10-成员杂芳基；所有基团均可选择性地被取代。
• [EN] MOLECULAR PROBES FOR DETECTING GRAM-NEGATIVE BACTERIA IN VITRO AND IN VIVO<br/>[FR] SONDES MOLÉCULAIRES POUR DÉTECTER DES BACTÉRIES GRAM NÉGATIF IN VITRO ET IN VIVO
  申请人：UNIV EDINBURGH

  公开号：WO2016075483A1

  公开（公告）日：2016-05-19

  A probe is provided comprising a label and a binding moiety, wherein the binding moiety is adapted to bind to gram-negative bacteria, and to substantially not bind to animal cells or gram-positive bacteria. A method of detecting the presence of bacteria in a target area is also provided, which allows the detection of bacteria generally, and the determination of whether that bacteria is gram negative or gram positive.

  提供一种探针，包括一个标签和一个结合基团，其中结合基团适用于结合革兰氏阴性细菌，并且基本不结合动物细胞或革兰氏阳性细菌。还提供了一种检测目标区域中细菌存在的方法，该方法允许通常检测细菌，并确定该细菌是革兰氏阴性还是革兰氏阳性。
• [EN] FRET MOLECULAR PROBES WITH CLEAVABLE LINKERS FOR DETECTING BACTERIA AND/OR FUNGI IN VITRO AND IN VIVO<br/>[FR] SONDES MOLÉCULAIRES FRET AVEC LIEURS CLIVABLES PERMETTANT DE DÉTECTER DES BACTÉRIES ET/OU DES CHAMPIGNONS, IN VITRO ET IN VIVO
  申请人：UNIV EDINBURGH

  公开号：WO2016075481A1

  公开（公告）日：2016-05-19

  An optical probe is provided comprising a probe element connected to a quencher by a cleavable linker; the probe element comprising a binding moiety, and a fluorophore being substantially fluorescently quenched by the quencher when the probe element is connected to the quencher by the cleavable linker; wherein the probe element is separated from the quencher when the cleavable linker is cleaved. Methods of using the probe are also provided.

  提供了一种光学探针，包括通过可切割连接物连接到猝灭剂的探针元件；所述探针元件包括结合基团和荧光物质，当通过可切割连接物将探针元件连接到猝灭剂时，荧光物质被猝灭剂大幅熄灭荧光；当可切割连接物被切割时，探针元件与猝灭剂分离。还提供了使用该探针的方法。